CEL-SCI Takes Delivery of Manufacturing Facility

CEL-SCI Corp. has taken delivery of the new manufacturing facility for its lead drug candidate Multikine. This facility, located in the Baltimore area, will produce Multikine for use in CEL-SCI’s Phase III trial for first-line therapy of previously untreated head and neck cancer, and for manufacturing the drug upon approval. The facility cost about $22 million to build and will soon be commercially ready. Currently the facility can produce about $600 million worth of drug per year and can be built out to produce nearly $2 billion worth of drug product per year.
    
Geert Kersten, CEL-SCI’s chief executive officer, said, “Having our own Multikine dedicated manufacturing facility gives us control and eliminates a great deal of risk from our product development. Our next step is to completely validate the facility and to bring it on line for manufacturing.”
   
CEL-SCI’s upcoming Phase III trial is an 800-patient study designed to demonstrate that administration of Multikine to head and neck cancer patients before they receive any conventional cancer treatment will increase their survival. Head and neck cancer affects about 650,000 people per year.